<?xml version="1.0" encoding="UTF-8"?>
<results title="funder">
 <result pre="transmembrane domain and the cytoplasmic signal domain [12]. The structural" exact="basis" post="for TLR3 interaction with dsRNA is the extracellular variable"/>
 <result pre="to induce synthesis of IFN and other cytokines is a" exact="basis" post="for diversity of their immunomodulatory properties. It has been"/>
 <result pre="viruses [51], some fungi contain dsRNA elements [52]. On the" exact="basis" post="of this type of dsRNA, Ridostin and Larifan preparations"/>
 <result pre="lower than of PolyG:PolyC and PolyI:PolyC [61]. Currently, on the" exact="basis" post="of PolyA:PolyU, the drug Poludan (manufactured by Lance-Farm LLC,"/>
 <result pre="B16BL6 melanoma. dsRNA delivery systems are also developed on the" exact="basis" post="of inorganic molecules. For example, iron oxide nanoparticles were"/>
 <result pre="(MUC1). However, fully synthetic glycopeptide tumor vaccines created on the" exact="basis" post="of this glycopeptide are characterized by low immunogenicity. Glaffig"/>
</results>
